GEO Specialty Chemicals sold to CPS Performance MaterialsJones Day advised funds affiliated with DWS Group, the asset management arm of Deutsche Bank, and Solus Alternative Asset Management in connection with the sale of GEO Specialty Chemicals, a manufacturer of specialty chemicals for customers in the United States and internationally, to CPS Performance Materials, a portfolio company of Arsenal Capital Partners, a private equity firm that specializes in control investments in specialty industrials and healthcare businesses.
CORSAIR acquires ORIGIN PCJones Day advised CORSAIR®, a portfolio company of EagleTree Capital and manufacturer of high-performance gaming peripherals and enthusiast components, in connection with the acquisition of custom gaming PC manufacturer, ORIGIN PC.
Cineworld Group completes asset monetization strategies in United States through cinema sale-leaseback transactionsJones Day advised UK headquartered, Cineworld Group PLC in connection with an asset monetization strategy in the United States involving a combined cash consideration of $556.3 million cinema sale-leaseback transactions to convert a substantial portion of Cineworld’s U.S. real estate holdings into cash to leverage its equity and optimize efficiency.
Finacity Corporation acquired by Greensill CapitalJones Day advised Finacity Corporation, a leader in specialized receivables securitization, in its acquisition by Greensill Capital, the leading non-bank provider of working capital finance for companies globally.
Funds managed by Invesco Asset Management Limited participate in $80 million PIPE investment in Evofem BiosciencesJones Day advised funds managed by Invesco Asset Management Limited in their participation in an $80 million PIPE investment in Evofem Biosciences, Inc., a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health.
Royalty Pharma acquires EMGALITY® royalty from Arteaus Therapeutics for $260 millionJones Day advised Royalty Pharma, the industry leader in acquiring pharmaceutical royalties, in its $260 million acquisition of the royalty interest held by Arteaus Therapeutics, LLC on future global net sales of Eli Lilly and Company’s EMGALITY® (galcanezumab), an anti-CGRP antibody for the prevention of migraine.
Trico Group acquires Performance Pumps business of UCI International HoldingsJones Day advised Trico Group Holdings, LLC in connection with its acquisition of the Performance Pumps business of UCI International Holdings.
GE Healthcare collaborates with Preventice Solutions Group to develop ambulatory cardiac arrhythmia monitoring suiteJones Day advised GE Healthcare in its collaboration with Preventice Solutions Group to develop an ambulatory cardiac arrhythmia monitoring suite for diagnostic purposes outside of hospitals or clinics.
Funds managed by Invesco Asset Management Limited participate in $27 million Series C financing round of Vedanta BiosciencesJones Day advised funds managed by Invesco Asset Management Limited in connection with their participation in the $27 million Series C financing round of Vedanta Biosciences, Inc., a clinical-stage company developing therapies for immune-mediated diseases based on human microbiome-derived bacteria.
Fonds InnoBio acts as selling shareholder in reverse merger of Millendo Therapeutics with OvaScienceJones Day advised Fonds InnoBio, managed by Bpifrance, in connection with the reverse merger of Millendo Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases, with OvaScience, Inc. in an all-stock transaction, and concurrent equity financing.
Funds managed by Invesco Asset Management Limited participate in $52 million Series B financing round of Spin MemoryJones Day represented Invesco Asset Management Limited in connection with its participation in the $52 million Series B financing round of Spin Memory, Inc., a provider of a comprehensive embedded magnetoresistive random access memory solution.
CORSAIR acquires Elgato GamingJones Day advised Corsair Gaming, Inc., a portfolio company of EagleTree Capital, in connection with the acquisition of the gaming division of Elgato Systems GmbH, which develops, designs and manufactures video game streaming software and hardware products.
Eni invests in Commonwealth Fusion SystemsJones Day represented Eni S.p.A. in its investment in Commonwealth Fusion Systems LLC, a spin-off from MIT that is developing superconducting magnet technology to accelerate the path to commercial fusion energy.
Funds managed by Invesco Asset Management Limited invest in GelesisJones Day advised Invesco Asset Management Limited in connection with its equity investment in Gelesis, Inc., a clinical stage biotechnology company focused on the development of first-in-class products to safely induce weight loss and improve glycemic control.
Funds managed by Invesco Asset Management Limited invest in Spin Transfer TechnologiesJones Day advised Invesco Asset Management Limited in connection with its investment in Spin Transfer Technologies, Inc., a leading developer of high-speed, high-endurance next generation memory technology.
Groupe Solmax acquires GSE Environmental from Littlejohn & Co. and Strategic Value PartnersJones Day acted as international counsel to Groupe Solmax, Inc., a Canadian-based industry leader in the production of high-quality polyethylene geomembranes for industrial and environmental applications, in connection with the acquisition and related financing of GSE Environmental, a global industry leader in the production of polyethylene geomembranes for industrial and environmental applications, from Littlejohn & Co. and Strategic Value Partners.
Alizé Pharma SAS acquired by Millendo Therapeutics, Inc.Jones Day advised Alizé Pharma SAS, a French clinical-stage biotech private company, in connection with its sale in a stock-for-stock transaction to Millendo Therapeutics, Inc., a U.S. clinical-stage biotech private company focused on developing novel treatments for endocrine diseases.
GE Healthcare and Roche enter partnership to develop integrated digital diagnostics platformJones Day advised GE Healthcare in its strategic partnership with Roche to develop an integrated digital diagnostics platform relating to oncology and critical care treatment.
StepStone forms joint venture with Milhaus, acquires five multifamily developments, and forms additional joint venture with Milhaus for acquisition of multifamily development project located in MissouriJones Day represented StepStone Group LP in connection with the (i) formation of a joint venture with Milhaus and the acquisition by such entity of five multifamily developments located in Indiana, Oklahoma and Tennessee, and (ii) formation of an additional development joint venture with Milhaus for the acquisition of a multifamily development project located in Missouri and capital commitments for the acquisition of additional multifamily development projects.
Verizon sells its cloud and managed hosting service to IBMJones Day advised Verizon Communications, Inc. in the sale of its cloud and managed hosting service to International Business Machines Corporation.
The following represents experience acquired prior to joining Jones Day.
Represented The Depository Trust & Clearing Corporation in its proposed sale of Clarient Global LLC and Avox Limited to Thomson Reuters.
Represented York Capital Management on its acquisition of utility-scale solar power generation projects from NARENCO Development and its formation of a renewable energy investment platform.
Represented WorldStrides International, a Carlyle Group portfolio company, on its acquisition of CBL International.
Represented CPA Global Limited, a Cinven portfolio company, on its acquisitions of Innography, Inc. and Landon IP, Inc.
Represented Auven Therapeutics on the sale of its portfolio company, Spirogen Sàrl, to AstraZeneca plc for aggregate consideration of up to US$440 million.
Represented 3i Group on its US$395 million acquisition of the Active Pharmaceutical Ingredients division of Alpharma Inc.
Represented McArthurGlen Europe on its €435 million European designer outlet center joint venture with Simon Property Group.
Represented BP on its US$650 million sale of oil and gas assets in the Gulf of Mexico to Marubeni and on the sale of solar power generation plants in Italy and Spain.
Represented National Grid on the sale of its U.S. service contract business to Homeserve.
Represented Hastings Funds Management and JPMorgan Asset Management on their US$840 million acquisition of a portfolio of U.S. power generation assets from Black Hills Corporation.
Represented CPA Global on its acquisitions of Innography, Inc. and of Landon IP Inc.
Represented Aptiv Solutions on its US$143.5 million acquisition by ICON plc.
Represented PTT Chemical Public Company Limited on its US$150 million investment in Natureworks, a subsidiary of Cargill, and a related bioplastics manufacturing joint venture.
Represented Firstsource Solutions Limited on its US$330 million acquisition of MedAssist Holding from RoundTable Healthcare Partners.
Represented Bank of America Merrill Lynch, Goldman Sachs, Morgan Stanley, UBS, GETCO, and Quantlab Financial on their minority consortium investment in Chi-X Global Holdings.
Represented Bank of America Merrill Lynch on its investment in Tora Holdings and related technology services and infrastructure arrangements.